Hepatitis C virus infection, chronic: Ribavirin, in combination with direct-acting antivirals, is recommended in the AASLD/IDSA guidelines as part of an alternative regimen for certain clinical scenarios. Hepatitis C treatment guidelines are constantly changing with the advent of new treatment therapies and information; consult current clinical practice guidelines for the most recent treatment recommendations. The combination of peginterferon and ribavirin, even with additional preferred HCV antiviral agent(s), is not recommended for hepatitis C virus (HCV) (regardless of genotype) in HCV adult treatment guidelines (treatment-naive or treatment-experienced). Peginterferon and ribavirin-based regimens, however, may remain in use in resource-limited settings where interferon-free regimens are inaccessible or unavailable (AASLD/IDSA 2018).